Theratechnologies Concludes Acquisition Process
Theratechnologies Inc. (NASDAQ: THTX), a pioneering biopharmaceutical company, has triumphantly concluded its acquisition by Future Pak, LLC. This strategic move marks a significant milestone for both the company and its shareholders, as it transitions to a fresh operational phase.
Understanding the Acquisition Details
Under this acquisition plan, executed through a structured arrangement, CB Biotechnology, LLC, an associate of Future Pak, has successfully acquired all outstanding common shares of Theratechnologies. The shares have been valued at US$3.01 each, along with additional contingent value rights (CVRs), which could yield aggregated cash payments up to US$1.19 per share based on specific performance milestones.
Implications for Shareholders
Shareholders can expect to receive their acquisition considerations through Computershare Investor Services Inc., the designated depositary. Payments will occur promptly following the submission of required documents from shareholders, reflecting a commitment to transparency and efficiency during this transition.
Understanding the Contingent Value Rights
The additional CVRs represent an exciting opportunity for shareholders, as they offer potential extra returns contingent upon reaching predetermined targets. With an independent assessment determining each CVR's fair market value to be US$0.80, this adds an appealing layer to the acquisition.
Future Steps Post-Acquisition
As a result of this acquisition, Theratechnologies plans to delist its shares from both the Toronto Stock Exchange and the Nasdaq, as part of their long-term strategy. They aim to maintain a streamlined operation unaffected by ongoing public reporting obligations, thereby optimizing their focus on innovation and growth.
About Theratechnologies Inc.
Theratechnologies is dedicated to delivering innovative biopharmaceuticals designed to enhance patient outcomes and redefine the standards of care in critical areas. Its mission is to drive advancements in healthcare, with an eye on the evolving needs of patients globally. For more information, visit www.theratech.com.
About Future Pak
Founded in 1977 and based in Wixom, Michigan, Future Pak specializes in contract manufacturing and packaging of pharmaceutical and nutraceutical products. Their commitment to quality and patient-centric solutions positions them as a leader in the industry, serving a diverse range of markets.
Frequently Asked Questions
What prompted Theratechnologies' acquisition by Future Pak?
The acquisition is aimed at streamlining operations and enhancing shareholder value through strategic alignment with Future Pak’s capabilities in biopharmaceutical production.
How will this affect current shareholders of Theratechnologies?
Current shareholders will receive payments for their shares along with potential additional cash from CVRs if specific milestones are met.
What are Contingent Value Rights (CVRs) and their value?
CVRs are rights entitling shareholders to additional payments based on the company's performance, currently valued at US$0.80 per CVR.
When will the delisting from stock exchanges occur?
Theratechnologies expects to complete the delisting of its shares from the relevant stock exchanges in the coming days following the acquisition.
Where can I find more information about Theratechnologies?
For detailed information, visit Theratechnologies' official website at www.theratech.com.
